Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitis.

ABSTRACT: Aim: Etrasimod and ozanimod are selective sphingosine 1-phosphate receptor modulators targeting the S1P_1,4,5, and S1P_1,5 receptors, respectively, for the treatment of patients with moderately to severely active ulcerative colitis (UC). No head-to-head trial data exist between the two treatments. We compared these treatments indirectly using key efficacy outcomes from pivotal trials with induction and maintenance phase data adjusting for differences in clinical trial design and populations. Materials & methods: Individual patient data for etrasimod were matched to published aggregate data of ozanimod by key baseline characteristics. An anchored matching-adjusted indirect comparison (MAIC) was conducted for the induction period. An unanchored MAIC was util

SUBMITTER: Jairath V 

PROVIDER: S-EPMC11963346 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature